vs
KEWAUNEE SCIENTIFIC CORP（KEQU）与RIGEL PHARMACEUTICALS INC（RIGL）财务数据对比。点击上方公司名可切换其他公司
KEWAUNEE SCIENTIFIC CORP的季度营收约是RIGEL PHARMACEUTICALS INC的1.0倍（$70.1M vs $69.8M），RIGEL PHARMACEUTICALS INC净利率更高（384.0% vs 3.5%，领先380.5%），KEWAUNEE SCIENTIFIC CORP同比增速更快（46.8% vs 21.2%），过去两年RIGEL PHARMACEUTICALS INC的营收复合增速更高（53.7% vs 22.4%）
基沃尼科学公司是实验室家具、通风柜及一体化实验室基础设施解决方案的专业供应商，服务覆盖制药、生物技术、学术研究、医疗健康、工业研发等领域，核心市场为北美地区，同时正在稳步拓展全球客户网络。
Rigel制药是一家临床阶段生物技术企业，专注于研发及商业化针对自身免疫性疾病、炎症性疾病与血液疾病的靶向小分子疗法，核心市场位于美国，旗下已获批产品可治疗成人免疫性血小板减少症，致力于满足未被覆盖的临床医疗需求。
KEQU vs RIGL — 直观对比
营收规模更大
KEQU
是对方的1.0倍
$69.8M
营收增速更快
KEQU
高出25.6%
21.2%
净利率更高
RIGL
高出380.5%
3.5%
两年增速更快
RIGL
近两年复合增速
22.4%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $70.1M | $69.8M |
| 净利润 | $2.4M | $268.1M |
| 毛利率 | 28.1% | 91.5% |
| 营业利润率 | 5.9% | 33.2% |
| 净利率 | 3.5% | 384.0% |
| 营收同比 | 46.8% | 21.2% |
| 净利润同比 | -18.7% | 1769.2% |
| 每股收益（稀释后） | $0.82 | $14.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收KEQURIGL
| Q4 25 | $70.1M | $69.8M | ||
| Q3 25 | $71.1M | $69.5M | ||
| Q2 25 | $77.1M | $101.7M | ||
| Q1 25 | $67.2M | $53.3M | ||
| Q4 24 | $47.8M | $57.6M | ||
| Q3 24 | $48.4M | $55.3M | ||
| Q2 24 | $56.7M | $36.8M | ||
| Q1 24 | $46.8M | $29.5M |
净利润KEQURIGL
| Q4 25 | $2.4M | $268.1M | ||
| Q3 25 | $3.1M | $27.9M | ||
| Q2 25 | $4.8M | $59.6M | ||
| Q1 25 | $1.4M | $11.4M | ||
| Q4 24 | $3.0M | $14.3M | ||
| Q3 24 | $2.2M | $12.4M | ||
| Q2 24 | $11.0M | $-1.0M | ||
| Q1 24 | $2.5M | $-8.2M |
毛利率KEQURIGL
| Q4 25 | 28.1% | 91.5% | ||
| Q3 25 | 29.4% | 93.2% | ||
| Q2 25 | 31.2% | 95.6% | ||
| Q1 25 | 27.4% | 91.7% | ||
| Q4 24 | 29.2% | 89.9% | ||
| Q3 24 | 25.8% | 85.5% | ||
| Q2 24 | 25.8% | 92.4% | ||
| Q1 24 | 25.7% | 93.1% |
营业利润率KEQURIGL
| Q4 25 | 5.9% | 33.2% | ||
| Q3 25 | 6.8% | 40.9% | ||
| Q2 25 | 11.0% | 60.1% | ||
| Q1 25 | 3.3% | 23.9% | ||
| Q4 24 | 9.3% | 28.9% | ||
| Q3 24 | 5.3% | 25.4% | ||
| Q2 24 | 9.8% | 1.2% | ||
| Q1 24 | 8.1% | -23.6% |
净利率KEQURIGL
| Q4 25 | 3.5% | 384.0% | ||
| Q3 25 | 4.3% | 40.2% | ||
| Q2 25 | 6.3% | 58.6% | ||
| Q1 25 | 2.0% | 21.5% | ||
| Q4 24 | 6.3% | 24.9% | ||
| Q3 24 | 4.5% | 22.5% | ||
| Q2 24 | 19.4% | -2.8% | ||
| Q1 24 | 5.4% | -27.9% |
每股收益（稀释后）KEQURIGL
| Q4 25 | $0.82 | $14.11 | ||
| Q3 25 | $1.04 | $1.46 | ||
| Q2 25 | $1.63 | $3.28 | ||
| Q1 25 | $0.45 | $0.63 | ||
| Q4 24 | $1.01 | $0.82 | ||
| Q3 24 | $0.74 | $0.70 | ||
| Q2 24 | $3.74 | $-0.06 | ||
| Q1 24 | $0.85 | $-0.47 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $12.6M | $155.0M |
| 总债务越低越好 | $35.3M | $52.5M |
| 股东权益账面价值 | $69.9M | $391.5M |
| 总资产 | $189.1M | $513.6M |
| 负债/权益比越低杠杆越低 | 0.50× | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资KEQURIGL
| Q4 25 | $12.6M | $155.0M | ||
| Q3 25 | $19.5M | $137.1M | ||
| Q2 25 | $14.9M | $108.4M | ||
| Q1 25 | $9.5M | $77.1M | ||
| Q4 24 | $26.0M | $77.3M | ||
| Q3 24 | $24.2M | $61.1M | ||
| Q2 24 | $23.3M | $49.1M | ||
| Q1 24 | $21.3M | $49.5M |
总债务KEQURIGL
| Q4 25 | $35.3M | $52.5M | ||
| Q3 25 | $37.4M | $60.0M | ||
| Q2 25 | $37.7M | $60.0M | ||
| Q1 25 | $38.0M | $60.0M | ||
| Q4 24 | — | $60.0M | ||
| Q3 24 | — | $60.0M | ||
| Q2 24 | — | $60.0M | ||
| Q1 24 | — | $60.0M |
股东权益KEQURIGL
| Q4 25 | $69.9M | $391.5M | ||
| Q3 25 | $67.1M | $117.6M | ||
| Q2 25 | $64.5M | $81.9M | ||
| Q1 25 | $60.8M | $18.6M | ||
| Q4 24 | $59.3M | $3.3M | ||
| Q3 24 | $56.0M | $-14.6M | ||
| Q2 24 | $54.8M | $-29.9M | ||
| Q1 24 | $44.1M | $-31.7M |
总资产KEQURIGL
| Q4 25 | $189.1M | $513.6M | ||
| Q3 25 | $193.5M | $242.5M | ||
| Q2 25 | $194.7M | $206.7M | ||
| Q1 25 | $189.1M | $176.0M | ||
| Q4 24 | $134.5M | $164.0M | ||
| Q3 24 | $132.0M | $139.4M | ||
| Q2 24 | $134.8M | $128.4M | ||
| Q1 24 | $126.3M | $126.5M |
负债/权益比KEQURIGL
| Q4 25 | 0.50× | 0.13× | ||
| Q3 25 | 0.56× | 0.51× | ||
| Q2 25 | 0.58× | 0.73× | ||
| Q1 25 | 0.62× | 3.23× | ||
| Q4 24 | — | 18.25× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.3M | $22.0M |
| 自由现金流经营现金流 - 资本支出 | $-5.8M | — |
| 自由现金流率自由现金流/营收 | -8.3% | — |
| 资本支出强度资本支出/营收 | 2.2% | — |
| 现金转化率经营现金流/净利润 | -1.74× | 0.08× |
| 过去12个月自由现金流最近4个季度 | $5.1M | — |
8季度趋势，按日历期对齐
经营现金流KEQURIGL
| Q4 25 | $-4.3M | $22.0M | ||
| Q3 25 | $5.8M | $24.0M | ||
| Q2 25 | $9.4M | $30.5M | ||
| Q1 25 | $-2.3M | $-893.0K | ||
| Q4 24 | $8.4M | $14.5M | ||
| Q3 24 | $-794.0K | $21.7M | ||
| Q2 24 | $1.1M | $302.0K | ||
| Q1 24 | $9.5M | $-5.0M |
自由现金流KEQURIGL
| Q4 25 | $-5.8M | — | ||
| Q3 25 | $5.0M | — | ||
| Q2 25 | $8.9M | — | ||
| Q1 25 | $-3.0M | — | ||
| Q4 24 | $7.8M | — | ||
| Q3 24 | $-1.1M | — | ||
| Q2 24 | $166.0K | — | ||
| Q1 24 | $9.0M | — |
自由现金流率KEQURIGL
| Q4 25 | -8.3% | — | ||
| Q3 25 | 7.1% | — | ||
| Q2 25 | 11.5% | — | ||
| Q1 25 | -4.4% | — | ||
| Q4 24 | 16.2% | — | ||
| Q3 24 | -2.2% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 19.3% | — |
资本支出强度KEQURIGL
| Q4 25 | 2.2% | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 0.7% | — | ||
| Q1 25 | 1.0% | — | ||
| Q4 24 | 1.4% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 1.7% | — | ||
| Q1 24 | 1.0% | — |
现金转化率KEQURIGL
| Q4 25 | -1.74× | 0.08× | ||
| Q3 25 | 1.87× | 0.86× | ||
| Q2 25 | 1.94× | 0.51× | ||
| Q1 25 | -1.67× | -0.08× | ||
| Q4 24 | 2.80× | 1.01× | ||
| Q3 24 | -0.36× | 1.75× | ||
| Q2 24 | 0.10× | — | ||
| Q1 24 | 3.77× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
KEQU
| Transferred Over Time | $32.9M | 47% |
| Transferred At Point In Time | $22.3M | 32% |
| Other | $14.9M | 21% |
RIGL
暂无分部数据
